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Abstract 
Background: Synthetic lethality (SL) refers to the genetic interaction between two or more 
genes where only their co-alteration (e.g. by mutations, amplifications or deletions) results in 
cell death. In recent years, SL has emerged as an attractive therapeutic strategy against 
cancer: by targeting the SL partners of altered genes in cancer cells, these cells can be 
selectively killed while sparing the normal cells. Consequently, a number of studies have 
attempted prediction of SL interactions in human, a majority by extrapolating SL interactions 
inferred through large-scale screens in model organisms. However, these predicted SL 
interactions either do not hold in human cells or do not include genes that are (frequently) 
altered in human cancers, and are therefore not attractive in the context of cancer therapy. 
Results: Here, we develop a computational approach to infer SL interactions directly from 
frequently altered genes in human cancers. It is based on the observation that pairs of genes 
that are altered in a (significantly) mutually exclusive manner in cancers are likely to 
constitute lethal combinations. Using genomic copy-number and gene-expression data from 
four cancers, breast, prostate, ovarian and uterine (total 3980 samples) from The Cancer 
Genome Atlas, we identify 718 genes that are frequently amplified or upregulated, and are 
likely to be synthetic lethal with six key DNA-damage response (DDR) genes in these 
cancers. By comparing with published data on gene essentiality (~16000 genes) from ten 
DDR-deficient cancer cell lines, we show that our identified genes are enriched among the 
top quartile of essential genes in these cell lines, implying that our inferred genes are highly 
likely to be (synthetic) lethal upon knockdown in these cell lines. Among the inferred genes 
include tousled-like kinase 2 (TLK2) and the deubiquitinating enzyme ubiquitin-specific-
processing protease 7 (USP7) whose overexpression correlate with poor survival in cancers.  
Conclusion: Mutual exclusivity between frequently occurring genetic events identifies 
synthetic lethal combinations in cancers. These identified genes are essential in cell lines, and 
are potential candidates for targeted cancer therapy. 
Keywords: Synthetic lethality; Mutual exclusivity; Context-dependent genetic vulnerabilities 
Reviewers: This article was reviewed by Dr Michael Galperin, Dr Sebastian Maurer-Stroh 
and Professor Sanghyuk Lee. 
 
1 Background 
Cells have evolved to ensure their viability. Although typically associated with survival (i.e. 
the ability to maintain homeostasis but not necessarily cell division), cell viability can be 
defined more broadly to encompass the ability to grow and proliferate. Processes within the 
cell ensure that it is sufficiently protected against deleterious genetic events – e.g. mutations, 
amplifications and deletions – that impact cell viability, but when these events are 
unavoidable the cell commits to apoptosis or programmed cell death.  
Genetic events can modify this control on cell viability, resulting in viability being enhanced 
(e.g. in cancer) or compromised (e.g. during cell senescence and death). This is effected by 
the (over-)activation or inactivation of genes responsible for cell viability through gain-of-
function or loss-of-function genetic events, respectively.  
When two or more of these genetic events occur simultaneously, these can considerably 
impact the viability of cells. Synthetic lethality (SL), first defined by Bridges in 1922 [1], 
refers to one such combination between two genetic events (typically affecting two different 
genes) in which their co-occurrence results in severe loss of viability or death of the cell, 
although the cell remains viable when only one of the events occurs [2,3]. 
SL has gained considerable attention over the last few years due to its value in understanding 
the essentiality of genes or their combinations [4,5], and more recently due to its promise as a 
therapeutic strategy for selective targeting of cancer cells [6,7]. Cancer cells are genetically 
different from normal cells and harbour genetic events in specific genes that enhance their 
viability. Therefore, by identifying and targeting (i.e. inducing a genetic event in) the 
synthetic-lethal partner of these genes, selective killing of cancer cells can be achieved while 
sparing the normal cells. SL-based therapies exploit these genetic differences in a way that is 
often not possible with conventional chemotherapy, which is often cytotoxic to normal as 
well as cancer cells [8].  
A pioneering breakthrough in SL-based cancer therapy showed that inhibition of poly(ADP-
ribose) polymerase (PARP) in cancer cells that harbour loss-of-function events in the breast-
cancer susceptibility genes BRCA1 and BRCA2 is dramatically lethal to these cells [9,10] 
(reviewed in [11]). Germline losses in BRCA1/BRCA2 are highly penetrant, conferring 60-
80% risk of breast and 30-40% risk of ovarian cancers. These losses account for about 10-
25% of hereditary breast and ovarian cancers [11,12]. 
Following the promise of BRCA-PARP, several studies have explored (computational) 
identification of SL interactions that could be efficacious in treating cancer. This began with 
seminal [13-15] and follow-up works [16-18] that studied “cross-talk” between pathways in 
model organisms including yeast, worm and fruit fly to characterise genetic interactions. 
From these studies emerged a between-pathway model [13,14] according to which loss of 
function in only one pathway does not greatly affect cell viability, but the further inactivation 
of a second parallel or compensatory pathway results in cell death. This model characterised 
synthetic lethal interactions as genetic interactions between these compensatory pathways. 
More-recent studies [19-21] have attempted extrapolation of SL interactions from model 
organisms (e.g. yeast http://drygin.ccbr.utoronto.ca/ [22] using protein-sequence homology to 
infer interactions in human cells – e.g. BRCA2-RAD52 [23], SMARCB1-PSMA4, 
ASPSCR1-PSMC2 [19] and between FEN1 and SMC3, RNF20, BLM, MRE11A, STAG3, 
CDC4 and CHTF18 [20,21]. Classification-based approaches [24-27] that employ a support 
vector machine trained with features from model organisms have also been used to predict 
new SL interactions in human, with the expectation that SL interactions follow similar 
organisational principles in human and model organisms. Recently Zhang et al. [28] proposed 
that single- and double-knockdown of proteins within known pathways could be 
computationally simulated to estimate interactions that are lethal; AKT with BID, CASP9 
and WEE1 were among the top SL interactions identified in human. Others [29-33] have 
employed combined experimental and computational approaches by performing knockdown 
of combinatorial pairs of genes using large-scale siRNA-screens across cell lines and in vivo 
models (e.g. http://www.genomernai.org/ [30]). These approaches have been more successful 
than the solely computational ones, resulting in identification of actionable SL-based targets, 
including GATA2 and CDC6 as SL partners of KRAS [29]. However, these approaches are 
considerably more expensive, and many of the essential genes so identified turn out to be 
either restricted to only these cell-line models or are infrequently overexpressed in cancers. 
Despite these attempts, interactions extrapolated from lower-order model organisms fail to 
hold up in human cells and are less-appealing in the context of cancer therapy. This is 
because the model systems, despite sharing some homologous proteins with human, have 
considerably different and simpler cellular and functional organisation [34,35]. While core 
cellular processes including cell-cycle and DNA-damage repair are broadly conserved, 
human cells express novel proteins, isoforms and/or paralogs with partially overlapping 
functions that buffer the loss of one another [34-37], with the consequence that lethality 
inducible by targeting only one of them is not conserved. For example, human cells have 
three AKTs – AKT1, AKT2 and AKT3 – with partially overlapping functions [38] whereas 
yeast has only one AKT. Similarly, SL interactions predicted from ‘static’ pathway maps do 
not reflect the actual scenario in cancer cells; these cells undergo significant pathway 
rewiring to enhance their viability [39,40]. Finally, these SL interactions do not include 
cancer genes or genes that are frequently altered in cancers – in particular, from the examples 
above, ASPSCR1, BLM, SMARCB1 and MRE11A put together are altered (homozygous 
deletion) in < 10% of most cancers as per The Cancer Genome Atlas (TCGA) Cbioportal 
cohort [41,42] – and therefore, the proportion of cancers benefiting from targeting their SL 
partners is very small. 
Here, we develop a computational approach taking into account the above factors by directly 
inferring SL interactions from frequently altered genes in cancers. We show that specific 
combinations of genes that display mutual exclusivity for genetic events are likely to 
constitute lethal combinations, and therefore by targeting these genes in conjunction could 
kill cancer cells. To demonstrate this, we consider six key DNA-damage response (DDR) 
genes that are frequently altered across four cancers – breast, prostate, ovarian and uterine – 
and using genomic copy-number and gene-expression data from TCGA [41,42], we identify 
genes that are altered in a (significantly) mutually exclusive manner with these six DDR 
genes. By comparing with data from genome-wide (~16000 genes) essentiality screens across 
ten DDR-deficient cancer cell lines [31,32], we show that our identified genes are enriched 
among the top quartile of essential genes in these cell lines, implying that our inferred genes 
are likely to be (synthetic) lethal upon knockdown in these cell lines. 
 
2  Methods 
Suppose that in a given large set of viable (cancer) cells, a pair of genes exhibits mutual 
exclusivity with respect to a genetic event – i.e. each gene individually is affected by the 
genetic event in most large proportions of cells but both genes are simultaneously affected in 
few or none. We hypothesize that the observed viability of these cells is dependent on, or a 
consequence of, the mutual exclusivity between the two genes: cells are not viable if the 
genetic event were to affect both genes simultaneously, and therefore we observe that few if 
any viable cells in our population carry such an event in both genes (in other words, the 
mutually exclusive combinations constitute the (clonally) selected combinations amenable to 
cell survival). Consequently, we infer that the two genes are synthetic lethal with each other. 
 
2.1 Mutual exclusivity between genetic events and inferring SL combinations 
Suppose that we are given an arbitrarily large set of viable (cancer) cells S. Let A and B be a 
pair of genes affected by a genetic event E in these cells S. Let SA (respectively, SB) be the 
subset of S in which A (respectively, B) is affected by E, and let SAB = SA ∩ SB.  The mutual 
exclusivity between A and B with respect to E can be defined as both |SA|/|SAB| and |SB|/|SAB| 
approaching infinity as |S| approaches infinity. Given this mutual exclusivity we infer that A 
and B are synthetic lethal with each other. 
Claim: |SA|/|SAB| and |SB|/|SAB| both approach infinity as |S| approaches infinity if, and only if, 
the co-occurrence of E in A and B affects cell viability, and therefore A and B are synthetic 
lethal with each other. 
Basis for the claim: Suppose the co-occurrence of E in A and B is lethal to the cells but not 
in either A or B alone. Then, SAB  = φ or a very small proportion of S. Therefore, |SA|/|SAB| and 
|SB|/|SAB| approach infinity when S is large. 
Conversely, |SA|/|SAB| and |SB|/|SAB| both approaching infinity implies that as event E in A 
occurs more often and E in B occurs more often, the co-occurrence of E in A and B occurs 
less often. But, if A and B are independent, we do not expect to see this pattern. So, the 
occurrences of E in A and B are avoiding each other in viable cells, and thus their co-
occurrence affects cell viability. 
 
 
2.2 Computing significant mutually exclusive gene combinations 
Let X be the random variable that counts the number of cells that show co-occurrence of a 
genetic event for the pair of genes (A, B). We estimate the statistical significance for the 
mutual exclusivity between A and B based on the probability of observing at most |SAB| cells 
(out of |SB| cells) with co-occurrence of the event (with |SA| cells). We estimate this 
probability P[X ≤ |SAB|] as 
P[X ≤ |SAB|] = 1 – P[X > |SAB|],   (Equation 1) 
where P[X > |SAB|] is computed using the hypergeometric probability mass function for X = k 
> |SAB|: 
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This “1 – hypergeometric test” p-value (Equation 1) is used to infer SL pairs (at p < 0.05), 
and the inferred pairs are ranked in order of their p-values. 
 
 
3  Results 
3.1  Datasets  
We gathered genomic copy-number and gene-expression datasets from four sporadic cancers, 
breast [43], prostate [44], ovarian [45] and uterine [46], from TCGA via Cbioportal 
(http://www.cbioportal.org/index.do) [41,42] and TCGA Firehose 
(http://gdac.broadinstitute.org/), composing a total of 3980 samples (Table 1). We consider 
four distinct genetic events: two kinds of genomic events (viz. gene copy-number 
amplifications and deletions), and two kinds of expression level events (viz. gene up- and 
downregulation). We expect that the changes in expression levels should encompass the 
effects of other kinds of events not directly considered here – e.g. mutations, chromatin 
changes and methylation. 
These copy-number and expression events are inferred from GISTIC-normalized [47] values 
available via Cbioportal [41,42] and TCGA Firehose. The copy-number value for each gene 
reflects the deviation in its number of copies from normal and is normalized to a range of [-2, 
2] where negative values represent deletions and positive values represent amplifications. We 
consider only high-level amplifications and deletions (typically homozygous deletions) 
having copy-number values +2 and -2, respectively. Likewise, the expression for each gene is 
z-score normalized, and here we consider genes that are highly upregulated or downregulated 
given by z-scores at least two standard deviations on either side of the mean (as per [41,42]). 
For more details on how these GISTIC-normalized values are computed, refer to [47]. 
To validate our predictions (genes B) we employed genome-wide (~16000 genes) essentiality 
data from siRNA-mediated knockdown screens across ten cancer cell lines that harbour a 
deficiency (mutation, deletion or downregulation) in at least one of the genes A (Table 2) 
[31,32]. These essentiality data are in the form of GARP (Gene Activity Rank Profile) scores 
for each gene and are approximately in the range [+5, -10] with a lower value in a cell line 
indicating higher essentiality for the gene in that cell line. 
 
 
3.2 Identifying mutually exclusive combinations involving frequently altered genes in 
cancers: a case study using six DNA-damage response genes  
Here we consider mutual exclusivity with deletion and downregulation events affecting the 
following six genes (as genes A): ATM, BRCA1, BRCA2, CDH1, PTEN and TP53. These are 
tumour-suppressor genes that are central to or regulate DNA-damage response (DDR) 
functions, that is, genes that play important roles in maintaining the genomic integrity of the 
cell and control cell proliferation [11]. These genes are deleted or downregulated across all 
the four cancers considered here, and their loss is a significant driver event in these cancers 
(TCGA, 2011; TCGA, 2012; TCGA, 2013; TCGA, 2014). To predict SL interactions, we 
identify genes B that are either amplified/upregulated or deleted/downregulated in a mutually 
exclusive manner to these genes A. Specifically, we identify two kinds of mutually exclusive 
combinations (SL interactions): (i) deletion/downregulation of gene A with 
amplification/upregulation of gene B; and (ii) deletion/downregulation of gene A with 
deletion/downregulation of gene B. 
 
  
3.2.1 Gene A deletion or downregulation with gene B amplification or upregulation 
We identified a total of 842 SL interactions involving 718 genes B at p<0.01. Figure 1a 
shows the distribution of these interactions with respect to the different genes A. BRCA2 
dominates the number of SL interactions followed by CDH1, PTEN and TP53, whereas ATM 
and BRCA1 participate in very few SL interactions. While these proportions are to an extent 
influenced by the actual fraction of cases in which these genes A are deleted/downregulated – 
PTEN (34%), CDH1 (12.9%), BRCA2 (9.8%), and TP53 (9.7%) are in much higher numbers 
than ATM (5.7%) and BRCA1 (4.8%) across all cancers – this still indicates that overall (i.e. 
across the four cancers) these six genes are involved to different extents in their synthetic 
lethality with amplification/upregulation of genes B. Moreover, there were fewer (<5%) 
overlaps between genes B partnered with different genes A, indicating considerable diversity 
in the SL landscape (Additional file 1).  
However, different genes A dominate the SL interactions within the individual cancers – e.g. 
CDH1 (99.5%) for breast, PTEN (78.4%) and BRCA2 (16.8%) for prostate and BRCA1 
(17.9%) and TP53 (16.2%) for ovarian cancers at p < 0.01, as shown in Figure 1b. These 
results indicate that SL interactions could be highly context-dependent (here, the type of 
cancer) with deletion/downregulation in different genes A dominating SL interactions within 
different cancers. Note that these analyses are based on uncorrected p-values (Equation 1) 
and are meant only to give a sense of the distribution of SL interactions; for the validation of 
genes B (below) we use the relative rankings of their p-values. 
 
 
3.2.2 Gene A deletion or downregulation with gene B deletion or downregulation 
The number of SL interactions involving both genes A and B deleted/downregulated were 
considerably fewer than in the previous case – a total of 143 interactions involving 117 genes 
B identified across all the four cancers at p < 0.05. As above, BRCA2, PTEN and CDH1 
dominate these SL interactions (Figure 2a) when all four cancers are taken together, whereas 
different genes dominate within the individual cancers – e.g. CDH1 (91%) and PTEN (9%) 
for breast, PTEN (88%) and BRCA2 (9%) for prostate, and CDH1 (58%) and BRCA1 (38%) 
for ovarian cancers. 
 
 
3.3 Computational validation using data from cell-line essentiality screens 
We expect that targeting genes B in conjunction with genes A could induce lethality. To 
validate this, we analysed the GARP essentiality scores of genes B in cell lines deficient with 
genes A. We chose ten cell lines (Table 2) that harbour a deficiency in at least one of the 
genes A [31,32]. The left-hand side plots of Figure 3 compare the ranges of GARP 
essentialities of our predicted genes B with that of the entire set of ~16000 profiled genes in 
these cell lines. While it is difficult to directly compare the two ranges because of the 
difference in number of genes in them, for the majority of cell lines the genes B at the 25th 
percentile had lower GARP scores than the corresponding genes from the entire profiled set. 
In particular, our predicted genes B were enriched significantly (χ2 test p<10-5) with the top-
quartile of essential genes (approximately the top 5000) from these ~16000 genes.  
We ranked our predicted genes B in increasing order of their mutual-exclusivity significance 
to generate a mutual-exclusivity (ME) ranking. Then, for each gene B that was among the top 
5000 we assigned a gene-essentiality (GE) rank as ‘5000 – rank of gene B in the essentiality 
screen’ (a reverse ranking). We then plot GE rank vs ME rank for all genes B for each cell 
line according to the gene-A deficiency it harbours. For example, since the cell line HCC1143 
harbours a deficiency in TP53 (Table 1), we plot GE rank vs ME rank for all genes B that are 
predicted as mutually exclusive with TP53 using the GARP score data for HCC1143. Doing 
so using the amplified/upregulated genes B resulted in the right-hand side plots shown in 
Figure 3. For all cell lines harbouring deficiencies in ATM, BRCA1, BRCA2, PTEN and TP53 
we see a downward trend, thereby indicating a strong agreement between the rankings based 
on mutual exclusivity and the GARP essentialities of our predicted genes B in gene A-
deficient cell lines (no data are available for cell lines with CDH1 deficiency). This analysis 
indicates that the genes B that are mutually exclusive with the loss of A in tumours are also 
essential in gene A-deficient cell lines, and therefore supports our hypothesis that the 
observed mutual exclusivity is very likely a mechanism to avoid cell lethality (thereby 
enhancing the essentiality of B). As these genes B are also (frequently) amplified/upregulated 
in the cancers, these could be attractive as targets in cancer therapy. 
Figure 4 shows similar plots using the deleted/downregulated genes B; however, since these 
genes are far fewer the plots show data for fewer gene ranks, the most being for PTEN. 
To understand whether the lethality observed for genes B is specific to A-deficient cell lines, 
we analysed the differential essentiality of B in the cell lines relative to the MCF7 cell line 
(due to lack of suitable data on normal cell lines, we chose MCF7 which is a typical luminal 
line with no known DDR defect, as our control for the comparison). We observed significant 
difference between the mean essentialities for B between the DDR-deficient and MCF7 cell 
lines (Figure 5a). Similar results were observed using data [32] from two HCT116-derived 
isogenic cell lines, one PTEN-/- and the other with wild-type PTEN (Figure 5b). This analysis 
indicated that the essentiality of B was highly specific to cell lines harbouring gene A 
deficiency, and hence B is synthetic lethal in the context of deficiencies in DDR genes. 
 
 
3.4  Case studies of identified SL partners B 
We expect that our predicted genes B that are amplified/upregulated to confer poor survival, 
and to validate this we plot the Kaplan-Meir curves for these genes using survival data from 
cancer patients (KMPlotter: http://www.kmplot.com/) [48]. Figure 6 shows examples for 
breast cancer (plots for ovarian cancer in Additional file 1). 
Several interesting genes are identified here – e.g. TLK2, which encodes the serine/threonine 
tousled-like kinase, is closely associated with the repair of DNA double-strand breaks (DSBs) 
and in the regulation of chromatin assembly during the S-phase (http://www.genecards.org/ ) 
[49]. TLK2 is amplified/upregulated in 26% of sporadic breast cancer cases, and confers 
significantly poor survival (p = 0.00072). In particular, GOBO-based analysis 
(http://co.bmc.lu.se/gobo/gobo.pl) [50] indicates that TLK2 is upregulated in 37% luminal 
(estrogen receptor (ER)-positive) breast tumours with grade 3-stratified multivariate analysis 
showing a hazard ratio of 2.25 (p=10-5) and poor survival (p<0.01) in these tumours 
(Additional file 1). 
Several interesting genes are identified here – e.g. TLK2, which encodes the serine/threonine 
tousled-like kinase, is closely associated with the repair of DNA double-strand breaks (DSBs) 
and in the regulation of chromatin assembly during S-phase [49]. TLK2 is 
amplified/upregulated in 26% of sporadic breast cancer cases, and its 
amplification/upregulation is mutually exclusive to BRCA2 deletion/downregulation. TLK2 
overexpression correlates with significantly poor survival (p = 0.00072) in these patients. In 
particular, GOBO-based analysis [50] indicates that TLK2 is overexpressed in 37% luminal 
(estrogen receptor (ER)-positive) breast tumours, and grade 3-stratified multivariate analysis 
indicates a hazard ratio of 2.25 (p=10-5) and poor survival (p<0.01) in patients with these 
tumours (Additional file 1). Interestingly, TLK2 overexpression can co-occur with PTEN loss 
or when PIK3CA, a key driver of ER-positive/luminal tumours, is not overexpressed. This 
also agrees with the high expression of TLK2 in luminal cell lines MCF7, MDA-MB-361 and 
SUM52PE which do not show high expression for PIK3CA (Additional file 1). Therefore, it 
is possible that TLK2 acts as a context-dependent driver of ER-positive/luminal tumours in 
the absence of PIK3CA expression. 
The ubiquitin specific peptidase USP7, which is a deubiquitinating enzyme, is 
amplified/overexpressed in ~40% of breast tumours in TCGA. USP7 is known to 
deubiquitinate target proteins including TP53 and PTEN. Overexpression of USP7 correlates 
with poor survival specifically in TP53-mutant patients (Additional file 1). 
EXOSC4 which encodes the EXOSC4 subunit of the RNA exosome complex that is 
important for RNA processing and degradation, is upregulated in 24% breast tumours, and 
confers poor survival (p=0.012).  
 
4 Discussion 
Our results demonstrate that there exist pairs (A, B) of genes that are altered in a mutually 
exclusive manner across tumours. We hypothesize that this observed mutual exclusivity 
could be a mechanism to avoid cell death, and consequently these pairs (A, B) constitute 
synthetic lethal combinations. To test our hypothesis, we use the essentialities (GARP scores) 
measured for genes B across cell-lines deficient in genes A (here, A includes six key DDR 
genes). We demonstrate that when our predicted genes B are ranked in order of their mutual 
exclusivity with A (as p-values), their ranks are consistent with that of their GARP scores in 
these A-deficient cell lines: the top-ranked genes B are also highly essential (lethal) to these 
cell lines. This is strongly suggestive that mutual exclusivity is an important mechanism to 
avoid lethality.  
Our approach is novel because we infer SL interactions directly from tumour data and 
validate these using essentiality data from tumour cell lines, and is different from earlier 
approaches [24-28]. Therefore, we effectively bypass several of the limitations of these 
approaches viz. inference of infrequently altered genes as SL partners, inference of genes 
solely from cell line models that may not hold in tumours, and inference of SL interactions 
from model organisms that do not hold in human [35].  
Beginning from the between-pathway model [13,14], synthetic lethality (SL) has often been 
associated with compensatory or parallel pathways, such that the loss of function of one of 
the pathways does not significantly affect cell viability whereas the loss of both pathways 
results in cell death (Figure 7a). Although this classical view gives an elegant explanation for 
SL, it only presents a partial one, mainly in terms of loss-of-function (inactivation) events. 
However, in general SL could also involve gain-of-functions (activation) events. Moreover, 
in the context of cancer, this model caters mainly to tumour-suppressor genes. For example, 
the loss of function in two parallel DNA-damage repair (tumour suppressor) pathways can 
lead to a considerable accumulation of DNA damage, resulting in genomic catastrophe and 
triggering apoptosis in cancer cells, as in the case of BRCA-PARP [11]. However, tumour-
suppressor genes in general can be difficult to target because of the (unknown) side-effects 
these could have on normal cells [51, 52], and because these are infrequently (over-) 
expressed in cancers to enable their targeting. Interestingly, many of the SL interactions that 
are extrapolated from lower-order organisms turn out to be tumour-suppressor genes (e.g. 
SMARCB1, see Introduction) and these are rarely altered in human cancers. We suspect that 
many of these highly conserved genes are much less susceptible to alterations than are newer 
inventions in humans, and consequently do not form attractive therapeutic targets in human 
cancers. 
Here, we extend these pathway models [13,14] to include gain-of-function (activation) events 
(Figure 7). In addition to the parallel-pathway model (Figure 7a) we propose a negative 
feedback-loop model (Figure 7b) wherein the forward path involves a gain-of-function event 
(often in an oncogene) whereas the negative-feedback loop involves a loss-of-function event 
(often in a tumour-suppressor gene). Cell viability is enhanced by activation events in the 
forward path or reciprocally by inactivation events in the negative-feedback loop. We 
hypothesize that, in the event of loss of a DDR gene in the negative-feedback loop, the 
simultaneous activation of an oncogene in the forward path could be detrimental to the cell’s 
survival by generating genomic instability. Consequently, to maintain an optimal condition 
for survival, cancer cells harbour only one of the two events resulting in mutual exclusivity 
between these events. We suspect the PIK3CA-PTEN combination is one such case: the PI3K 
pathway either harbours frequent activation events in the oncogenic PIK3CA kinase (96/156 
breast tumours) resulting in accelerated cell growth and proliferation or reciprocally frequent 
inactivation events in the tumour suppressor PTEN (67/156) resulting in loss of negative-
feedback to control cell proliferation; however we rarely see breast tumours harbouring both 
these events (8/156; p-value≈0) possibly due to their detrimental effect on cancer cell 
survivability.  
Likewise, the KRAS-NF1 combination also fits into this pathway model. Simultaneous 
activation of the KRAS oncogene together with inactivation of NF1 tumour suppressor could 
be lethal to cell survival, and hence these two events rarely co-occur (p-value = 0.001). 
Another example of SL is between BRCA1 and CCNE1, which although are not components 
of the same physical pathway, are functionally related due to their roles in the cell cycle and 
therefore broadly fit into our proposed model. BRCA1, being a tumour suppressor and a 
regulator of DNA-damage repair, has a reciprocal role to CCNE1 whose overactivation 
accelerates cell divisions and confers replication stress and genomic instability. CCNE1 
amplification/overexpression is mutually exclusive to BRCA1 deletion/underexpression in 
ovarian cancers (p-value = 0.073). Consequently, loss of BRCA1 is synthetic lethal to cells 
harbouring CCNE1 amplifications, and this has recently been validated using inhibition of 
BRCA1-mediated DNA repair in ovarian cancer cell lines [53]. 
While the induction of cell lethality for certain combinations of genetic events seems a 
compelling reason for the observed lack of tumour samples containing these combinations, an 
alternative explanation could be that cells use mutual exclusivity as a means to achieve 
multiplicity in phenotypes. For example, it is possible that PIK3CA activation and PTEN 
inactivation are two (disjoint) paths to achieve two distinct phenotypes. One observation in 
support of this is that PIK3CA-activated breast tumours tend to be luminal, whereas PTEN-
inactivated breast tumours tend to be basal-like [43]; however, harbouring simultaneous 
events in both genes is not additively advantageous to cells. A similar explanation also 
underlies the mutual exclusivity for KRAS and EGFR mutations seen in lung cancer [54]. 
Another example is CDH1-PTK2. Here, the tumour suppressor CDH1 is responsible for 
maintaining cell adhesion and regulating cell migration. The focal adhesion kinase PTK2 is 
responsible for disassembly of cell adhesions and promoting cell proliferation and migration. 
CDH1 inactivation is mutually exclusive to PTK2 activation in breast cancer (p-value = 
0.001). During tumour development and in particular during metastasis, the inactivation of 
CDH1 or alternatively the activation of PTK2 could be two disjoint paths to achieve cell 
migration to distant sites. 
 
4.1 Genes B as targets in cancer 
Consistent with these pathway models, we expect that targeting B in the context of 
deletion/downregulation of A could result in cancer-cell death by either disrupting both 
survival pathways (Figure 7a) or by shutting off (forward) signals for cell survival (Figure 
7b). In the latter case, targeting gene B irrespective of the (deletion/downregulation) status of 
A could result in cancer cell death, a scenario referred to as “oncogene addiction” [55,56]. 
Our proposed model (Figure 7b) subsumes this scenario, and hence presents a more-general 
strategy for targeting oncogenes under the synthetic lethality paradigm. 
 
 
5  Conclusion 
In recent years, SL has emerged as an attractive therapeutic strategy against cancer: by 
targeting the SL partners of altered genes, cancer cells can be selectively killed while normal 
cells are spared. Here we introduce a computational approach to infer SL interactions based 
on the frequency at which genes are altered in human cancers. It is based on the observation 
that pairs of genes that are altered in a (significantly) mutually exclusive manner in cancers 
are likely to constitute lethal combinations. Using omics datasets across breast, prostate, 
ovarian and uterine cancer, we identify 718 genes that are upregulated or amplified in 
cancers, and are likely to be synthetic lethal with six key DDR genes. Computational 
validation of our predicted genes using essentiality data from cell-line screens shows that 
these genes are among the top essential genes and therefore likely to be lethal upon 
knockdown in these cell lines. We intend to validate some of these genes using single- and 
double knockdown in cell line and in vivo cancer models. 
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RESPONSE TO REVIEWERS 
 
Reviewer 1 (Dr Michael Galperin) 
I support publication of this manuscript in its current form. 
Thank you for reviewing our manuscript and for your supportive comment. 
 
Reviewer 2 (Dr Sebastian Maurer-Stroh) 
The manuscript 'Inferring synthetic lethal interactions from mutual exclusivity of genetic events in 
cancer' is an interesting study outlining a new computational statistical approach to identify synthetic 
lethal (SL) pairs for potential targeting in cancer treatment from large-scale gene copy number and 
expression data with example validation against essentiality data from siRNA screens. The 
introduction gives an adequate overview of prior related work and the background context. The new 
approach hinges on the observation that there seems to be an inverse correlation between gene 
essentiality and mutual exclusivity of co-occurrence of genomic events with mutated tumor suppressor 
genes in the studied cell lines (right side panel of Figure 3). I have two main comments: 
1) While the correlation in Figures 3 and 4 (right panel) is certainly interesting, I am wondering how 
SPECIFIC the identified SL pairs are in these cases to the actual gene pairs. The Figure only shows 
data/lines for cell lines that have a defect in the respective DDR gene A for which the mutual 
exclusivity with genes B is calculated. It would be important to show also the data/lines for all other 
cell lines used here (maybe in weak gray color so they stay in the background) so one can see if the 
correlation is specific to the studied SL pair with gene A or possibly a general function of the 
essentiality of genes B. The latter could be seen if a similar correlation would appear independent of 
defect status of gene A. Pair specificity would be important for future clinical use since a specific link 
would mean that a genetic test for defects in gene A would be useful, while unspecific linkage would 
not require it. 
Thank you for this important comment. Certainly the specificity of our identified SL targets, or in 
other words, the differential essentiality/lethality of these targets in DDR-deficient cell lines vis-à-vis 
normal cell lines or in cell lines with proficient DDR, is an important concern. Due to lack of suitable 
data from normal cell lines, here we analyzed the differential essentiality of these genes relative to the 
MCF7 cell line, which is a typical luminal cell line that does not harbor any known DDR defect. In 
addition, we compared the essentialities of these genes between PTEN wild-type and PTEN-/- 
isogenic HCT116-derived cell lines (obtained from [32]) to understand differential essentiality in the 
context of PTEN loss. In both analyses, we observe significantly higher essentialities for our genes in 
DDR-deficient cell lines, thereby indicating that knockdown of these genes is more lethal specifically 
in the context of DDR defects. These analyses have now been added to Section 3.3 and as a new 
Figure 5. 
 
2) It would be a stronger argument for selected SL pairs if they can be mechanistically rationalized 
and discussed to a greater extent in their pathway context (e.g. double hit in same pathway or hit in 
two different redundant pathways). Maybe add 1 or 2 more explicit examples like the one for 
PIK3CA-PTEN in the discussion. 
This is again a very useful suggestion. We now discuss three other examples in the manuscript – 
BRCA1-CCNE1, KRAS-NF1 and CDH1-PTK2 under Discussion – to provide mechanistic explanation 
to our hypothesis. 
 
Reviewer 3 (Professor Sanghyuk Lee) 
The authors propose an intriguing hypothesis that synthetic lethality underlies the mutual exclusivity 
in cancer. Using the TCGA data sets of four cancers (3980 samples), they identified 718 genes that 
were mutually exclusive with six key DNA-damage response genes. Their rank correlation with the 
synthetic lethality measured in ten DDR-deficient cancer cell lines showed a strong linear 
relationship. Survival plots for several candidate genes showed significant separation, further 
supporting the hypothesis. 
The concept of inferring synthetic lethality from the mutual exclusivity is novel even though several 
studies (Ciriello G et al., Genome Research 2012; Unni AM et al., eLife 2015) asserted those two are 
related. Systematic mining of the TCGA data sets provides a solid ground for the hypothesis. 
There are several concerns that should be addressed: 
 
1. The box plots are not helpful at all. The authors need a better illustration showing that mutually 
exclusive genes were enriched in top quartile of essential genes. The rank correlation plot is 
confusing as well because of the reverse ranking for the gene essentiality. It would be more intuitive 
to take the positive correlation in the plot. 
The huge difference between the sizes of the two gene lists – our set of 718 genes vs ~16000 profiled 
genes – makes it difficult to have a better illustration for the side-by-side comparison between their 
GARP values. But, we mention this now in the caption of Figure 3. Hence, we report the Chi-square 
test p-value (p<10-5) for the enrichment of our genes in the top-quartile of all profiled genes across the 
different cell lines. 
We agree that showing the positive correlation might look more natural, but then if we were to plot 
using increasing ranks, we won’t know at which rank to stop. Therefore, here we put a cut-off and 
begin at rank 5000 (because this covers the top-quartile of the ~16000 genes into which our predicted 
genes mostly fall), and then go down until rank 0. This inverse plot helps to convey the idea that as 
we go down the ME ranks (i.e. with higher co-occurrence) the essentiality of gene B drops in cell 
lines. 
 
2. The authors show the Kaplan-Meier curves for candidate genes. It is not clear how the patients 
were divided into two groups of high and low. KM plots tend to depend on the choice of patient 
cohorts dramatically. The same tendency should be replicated using independent patient cohorts. I 
assume that there exist several well-known cohorts of breast cancer with gene expression data 
available in public. 
The patients were divided into two groups based on the expression levels of the genes in question, as 
patients overexpressing the genes (expression levels in the upper tertile) and patients underexpressing 
the genes (expression levels below the upper tertile). This information is now added to the Figure 6 
caption. 
We used KM Plotter [57] to plot the KM curves. KM Plotter already combines multiple cohorts 
covering more than 1800 patients to generate the curves. For some of the genes, we also used GOBO 
[50] which also combines several cohorts. 
 
3. To enhance the reliability of the assumption (i.e. synthetic lethality directly related to mutual 
exclusivity), it would be of great help to show well-known examples in the introductory part. EGFR-
KRAS in lung cancer was highlighted by a recent paper (Unni AM et al., eLife 2015). I expected a 
similar trend for the BRCA-PARP genes in breast cancer, but was puzzled to find that they do not 
seem to be mutually exclusive in a simple query to the cBioPortal. Do authors have any explanation? 
What happens to the MDM2-TP53 gene pair (Ciriello G et al., Genome Research 2012)? 
 
Synthetic lethality is a broader concept and in general covers any combination of genetic events that 
induces lethality in cells. Here, we only analyze expression up/downregulation and genomic 
amplification/deletion events affecting six DDR genes to study SL in the context of DDR defects. Our 
rationale behind focusing on DDR is that cells already deficient in DDR functions would be highly 
sensitive to further DNA damage, and therefore any event that triggers further accumulation of DNA 
damage – the upregulation/amplification of an oncogene that results in fast cell divisions, or the 
downregulation/deletion of a compensatory DDR gene that further weakens DNA-damage repair 
functions – could be highly lethal to the cells (genomic catastrophe). By basing on mutual exclusivity, 
we present a systematic approach to mine for SL cases, and demonstrate our approach on DDR genes; 
but the SL cases reported in the literature covering non-DDR genes might not be detected from our 
analysis. 
Moreover, lethality depends on the functions and essentialities of the affected genes – e.g. events 
affecting two genes might be avoiding one another (i.e. mutually exclusive) as a means to increase the 
number of possible paths to achieve distinct phenotypes, but their individual or simultaneous 
occurrence might not necessarily be lethal to the cells (see Discussion). Furthermore, several 
confounding factors – e.g. the existence of other events that rescue cells from lethality – could also 
affect these SL relationships. Some examples including BRCA-PARP and how cells are rescued from 
lethality via loss of 53BP1 are discussed below to further highlight these intricacies.  
The BRCA-PARP combination is the first successful example of a SL relationship that has seen 
clinical applicability in breast and ovarian cancers, to kill cancer cells deficient in BRCA1/2 (cells 
with ‘BRCAness’ property). Here, the PARP1 protein is a key component of the alternative non-
homologous end-joining (NHEJ) pathway which functions throughout the cell-cycle to repair double-
strand breaks (DSBs). PARP1 also plays an important role in restarting of stalled forks during DNA 
replication (S-phase) by directing DSBs (converted from stalled forks) towards BRCA-mediated 
homologous recombination (HR) pathway for DSB repair. The HR pathway mainly functions during 
the G1/S phase to repair DSBs arising during DNA replication. 
Consequently: (i) PARP, being part of the NHEJ machinery, functions throughout the cell cycle, and 
in general is overexpressed in fast-dividing cancer cells that harbour DNA breaks; but (ii) the 
functions of PARP and BRCA1-mediated repair overlap specifically during the DNA replication 
(G1/S-phase). In general, any query on cancer datasets (including Cbioportal for TCGA) would show 
PARP1 overexpressed in a considerable proportion of tumours. But, the synthetic lethality between 
BRCA1 and PARP applies to the small window during DNA replication where their functions 
become compensatory: in the event of loss of BRCA1, further inhibition of PARP results in 
accumulation of DSBs (because DSBs are not repaired or are repaired erroneously), thus leading to 
accumulation of lethal levels of DNA damage and consequently cell death. Therefore, PARP 
overexpression is not necessarily mutually exclusive to BRCA1 loss (i.e. PARP is not overexpressed 
only to compensate for BRCA1 loss), but their double loss is catastrophic and hence synthetic lethal 
to cells. 
Intriguingly, reports have also shown that an additional loss of 53BP1 can rescue cells BRCA-
deficient cells from lethality despite PARP inhibition [58]. This is an excellent example of where 
additional genetic events act as confounding factors to SL relationships, and is also suspected to be a 
mechanism to acquire drug resistance in cancers. 
Another interesting example is the synthetic lethality upon inhibition of checkpoint kinase CHEK1 
and cyclin-dependent kinase CDK1 in cells overexpressing the MYC oncogene [59-61]. Cells 
overexpressing MYC display accelerated cell divisions, and the resulting replication stress leads to 
accumulation of significant levels of DNA damage. Cell-cycle checkpoints arrest these cells with 
DNA damage and give them time to repair their damaged DNA. Inhibition of CHEK1/CDK results in 
the abrogation of cell-cycle checkpoints, and consequently the cells are forced to pass through 
checkpoints unstopped, leading to a genomic catastrophe and cell death. Here again, if we query 
cancer datasets, CHEK1/CDK being cell-cycle regulators, are seen overexpressed in most aggressive 
tumours (e.g. triple-negative breast cancers), and but are not necessarily mutually exclusive to MYC 
overexpression. However, CHEK1/CDK inhibition proves catastrophic to the fast-growing cells, and 
in that way CHEK1/CDK inhibition is lethal to cells overexpressing MYC. 
MDM2 is a negative regulator of TP53, and its overexpression inactivates TP53 functions. 
Consequently, even if some cancer cells have wild-type TP53, the overexpressing MDM2 prevents 
activation of TP53-mediated apoptotic program. Hence, inhibition of MDM2 releases the brakes on 
TP53, thus enabling cells to be arrested and driven down the path of programmed cell death. 
Therefore, here again, TP53-MDM2 does not necessarily show up as mutually exclusive in cancer 
datasets, but MDM2 inhibition induces lethality in cells by reactivating the TP53-mediated apoptotic 
program. 
EGFR-KRAS is a slightly different story. Here, cancer cells either harbour either EGFR mutations or 
alternatively KRAS mutations to confer tumorigenesis, but simultaneous events in both EGFR and 
KRAS are not additively advantageous to the cells, as also explained in Unni et al. [54]. Mutations in 
EGFR and KRAS might be two different ways of conferring cancer phenotypes, but simultaneous 
mutations in both the genes might be non-optimal for cancer cell survival, and in this way, mutations 
in EGFR and KRAS are synthetic lethal. This is now covered under Discussion. 
In summary, while synthetic lethality provides a logical explanation for the lack of certain co-
occurring (i.e. mutually exclusive) combinations, in general synthetic lethality is a broader concept. 
Moreover, most of the SL-based targets observed in the literature are pharmacologically induced (e.g. 
via CHEK1 inhibition), but alterations to these targets are not naturally occurring in tumours (CHEK1 
is not frequently lost in tumours), and this explains why some of these genes highlighted in the 
literature do not turn up in our list. 
 
4. According to the authors’ pathway models, I expect that the amplification/upregulation candidates 
(718 genes identified) would be enriched with oncogenes. The list of oncogenes can be obtained from 
various resources including the Cancer Gene Census, Vogelstein’s paper on 20/20 rules, and so on. 
This simple test would enhance the credibility of the pathway models. 
Four of our identified genes – PIK3CA, KRAS, GNAS and ASXL1 – appear in Vogelstein’s list of 
‘driver genes affected by subtle mutations’ (the 20/20 list) [62]. Three genes – PHOX2B, EXT1 and 
RECQL4 – appear in Vogelstein’s list of ‘cancer predisposition genes’, and one gene – MYC – 
appears in the list of ‘genes affected by amplifications or deletions’. Thus, in total eight of 718 genes 
in our list appear in Vogelstein’s lists, but our list is not enriched with Vogelstein’s listed genes. 
Our candidate genes are lethal upon inhibition in the context of DDR defects, as depicted by their 
relatively higher essentialities specifically in DDR-deficient cell lines. While some of our candidate 
genes constitute (universal) oncogenes (e.g. KRAS and PIK3CA), the roles of these genes can be 
understood only by considering the context of DDR defects. Depending on the status of certain DDR 
genes, our predicted genes can be oncogenic drivers (e.g. TLK2, which seems to be driving luminal 
breast tumours where PIK3CA expression is not high: Section 3.4), or vulnerability genes on which 
the survival of cells heavily depends (e.g. SMC4, which is required for structural maintenance of 
chromosomes and DNA repair, more so in the context of loss of key DDR genes). 
A recent report has noted a context-dependent oncogenic role for BRF2 (not a known oncogene in 
most cancers) in driving a subset of HER2+ breast tumours which do not express ERRB2/HER2 [63]; 
the authors call BRF2 an ‘alternative driver’ of HER2+ tumours.  
Therefore, although not enriched with genes from Vogelstein’s 20/20 list of universal oncogenes, our 
predicted genes include oncogenes that are activated in a context-dependent manner in tumours. A 
general method based on the frequency of overexpressed/amplified genes will not be able to identify 
these genes; but by adding a context, we can prioritise them statistically. Our method addresses this 
by identifying oncogenes in the context of DDR defects. 
 
5. There exist many methods of inferring synthetic lethality (as reviewed by the authors) and the 
mutual exclusivity. Although the authors describe limits of previous methods inferring synthetic 
lethality, it would be relieving to see a reasonable overlap between the author’s result and previous 
methods. 
The following oncogenes – PIK3CA, MYC, EGFR and CCNE1 – from our list are known oncogenes 
and have also been predicted by earlier methods. These genes are also being pursued as targets in 
clinical trials. However, other predicted genes from the literature including SMARCB1, MRE11A and 
ASPSCR1 [19] that have been inferred from lower-order organisms do not show up in our list. This is 
because these genes are infrequently altered in human cancers. As mentioned in Discussion, most of 
the genes predicted from morphologically simpler “model” organisms are highly conserved, and these 
are rarely altered in human cancers. Several of these genes are also tumour suppressors. As such, they 
are not worthwhile as anti-cancer targets. 
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Figures 
Figure 1: Proportions of synthetic lethal (mutually exclusive) interactions identified for each 
of the six DDR genes A (a) across all cancers; and (b) in the individual cancers of breast, 
prostate and ovarian (uterine cancer by itself has too few samples to identify any significant 
interactions) at three levels of significance (p < 0.01, 0.001 and 0.001). Here, the SL partners 
B are amplified/upregulated. 
 
Figure 2: Proportions of synthetic lethal (mutually exclusive) interactions identified for each 
of the six DDR genes A (a) across all cancers; and (b) in the individual cancers of breast, 
prostate and ovarian (uterine cancer by itself has too few samples to identify any significant 
interactions) at three levels of significance (p < 0.05 and 0.01). Here, the SL partners B are 
deleted/downregulated. 
 
Figure 3: Validation of synthetic lethal interactions against GARP essentiality scores from 
cell line screens [31,32]. The left-hand plots compare the ranges for GARP scores of our 
predicted genes B (amplified/upregulated) with that of the entire set (~16000) of profiled 
genes. While it is difficult to directly compare the two ranges because of the difference in the 
number of genes in them, for majority of the cell lines the gene B at the 25th percentile had 
lower GARP scores than the corresponding gene from the entire profiled set. By χ2 test, genes 
B were significantly enriched (p<10-5) within the top-quartile essential genes in these cell 
lines. The right-hand plots show GE ranks vs ME ranks for genes B in cell lines that are 
deficient in genes A: (a) ATM, (b) BRCA1, (c) BRCA2, (d) PTEN and (e) TP53.  
 
Figure 4: Validation of synthetic lethal interactions against GARP essentiality scores from 
cell line screens [31,32]. The left-hand plots compare the ranges for GARP scores of our 
predicted genes B (deleted/downregulated) with that of the entire set (~16000) of profiled 
genes. While it is difficult to directly compare the two ranges because of the difference in the 
number of genes in them, for majority of the cell lines the gene B at the 25th percentile had 
lower GARP scores than the corresponding gene from the entire profiled set. By χ2 test, genes 
B were significantly enriched (p<10-5) with the top-quartile essential genes in these cell lines. 
The right-hand plots show GE ranks vs ME ranks for genes B in cell lines that are deficient in 
genes A: (a) BRCA1, (b) BRCA2, and (c) PTEN.  
 
Figure 5: Differential essentiality of genes B (a) between nine DDR-deficient and MCF7 cell 
lines; and (b) between PTEN-/- and PTEN wild-type isogenic cell lines. We considered 
MCF7, which does not have any known DDR defect, as our control. Comparisons of GARP-
score means for genes B between DDR-deficient lines and MCF7 showed significant 
differences (ANOVA p<0.0001) between these cell lines. Similarly, comparison of GARP 
scores between two isogenic HCT116-derived cell lines, one with PTEN-/- and the other with 
wild type PTEN showed significant difference (paired t-test: p<0.0001) between the two cell 
lines. This analysis indicated that the essentiality/lethality of genes B is specific to DDR-
deficient/PTEN-deficient cell lines, and therefore context-dependent on DDR deficiency. 
 
Figure 6: Snapshot of the proportion of cases and Kaplan-Meier survival plots for predicted 
genes B (amplified/upregulated) using survival data (untreated) from 1000 breast cancer 
patients, plotted using KMPlotter-breast (http://www.kmplot.com/ [48]). The patients are 
divided into two groups based on the overexpression (upper tertile of expression levels) and 
underexpression (below the upper tertile of expression levels) for these genes. 
 
Figure 7: Two models for pathway-based targeting of synthetic lethal genes B in conjunction 
with deleted/downregulated genes A: (a) parallel pathways model where targeting B results in 
disruption of both survival pathways, and (b) negative feedback-loop model where targeting 
B shunts of (forward) signals for cell survival.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Tables 
 
Cancer Genomic Gene expression Total 
Breast 847 1182 2029 
Prostate 152 471 623 
Ovarian 562 266 828 
Uterine 443 57 500 
Total 2004 1976 3980 
 
Table 1: Number of genomic copy-number and gene-expression cancer samples used in the 
study. The datasets were downloaded for four cancers – breast, prostate, ovarian and uterine – from 
CBioportal (http://www.cbioportal.org/index.do) [41,42] and TCGA Firehose 
(http://gdac.broadinstitute.org/), giving a total of 3980 cancer samples. 
 
 
 
 
Table 2: Cell lines and the defects they harbour for DNA-damage response (DDR) genes. 
Genome-wide (~16000 genes) essentiality data [31,32] from ten cancer cell lines that harbour defects 
(mutations MUT, downregulation DOWN or homologous deletions HOMDEL) in at least one of the 
DDR genes ATM, BRCA1, BRCA2, PTEN and TP53. 
 
 
 
Cell line / Gene A ATM BRCA1 BRCA2 PTEN TP53 
HCC1500 
MUT; 
DOWN 
HCC1419 DOWN MUT 
HCC1395 DOWN MUT; DOWN MUT; DOWN MUT 
HCC1806 
HCC1143 MUT 
HCC38 DOWN DOWN 
MUT; 
HOMDEL 
HCC1187 DOWN DOWN 
HCC1954 DOWN MUT 
MCF7 DOWN 
HCC1428 DOWN HOMDEL 
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